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Abstract
Background: Oxaliplatin is a platinum compound used in the treatment of gastrointestinal malignancies, including
colorectal cancer. The incidence of hypersensitivity reaction in patients receiving oxaliplatin is approximately 15%,
with severe reaction (grade 3 and 4) occurring in 2% of patients.
Case presentation: We report two patients with metastatic colorectal cancer who developed de novo
hypersensitivity reaction and acute thrombocytopenia after oxaliplatin infusion. Both patients had oxaliplatin
treatment several years before and exhibited hypersensitivity on the third dose of oxaliplatin in recent treatment.
Oxaliplatin was discontinued when clinical reaction was identified. Both patients were confirmed to have strong
oxaliplatin-induced IgG platelet-reactive antibodies. Both patients’ thrombocytopenia resolved within two weeks
after discontinuation of oxaliplatin. One patient had disease stabilization lasting for three months without
chemotherapy. Both patients subsequently received other chemotherapeutic agents without evidence of
hypersensitivity reaction or immune-mediated thrombocytopenia.
Conclusion: We recommend vigilant monitoring of complete blood count and signs and symptoms of bleeding
after the occurrence of oxaliplatin-induced hypersensitivity to avoid serious complications of immune-mediated
thrombocytopenia.
Background
Oxaliplatin is a third-generation platinum derivative that
has been widely used in patients with gastrointestinal
malignancies including colorectal cancer (CRC). The
combination of 5-fluorouracil, leucovorin and oxaliplatin
(FOLFOX) has been demonstrated in several studies to
increase survival rate and reduce the risk of disease pro-
gression in patients with metastatic CRC and stage III
colon cancer [1,2]. Thrombocytopenia has been noted in
more than 70% of patients receiving FOLFOX., and is
usually self-limited and related to myelosuppression
from oxaliplatin [2]. The isolated and acute decline in
platelets after FOLFOX treatment is thought to be
immune-mediated, and is referred as drug-induced
immune thrombocytopenia (DIIT). Oxaliplatin-depen-
dent antibody against platelet glycoprotein IIb/IIIa
complex has been identified in patients with oxaliplatin-
induced immune thrombocytopenia [3].
The hypersensitivity reaction associated with oxalipla-
tin typically consists of rigors, fever, rash, tachycardia,
and dyspnea. The incidence in patients with CRC was
reported as high as 15% and mainly occurred shortly
after infusion in patients who had prior exposure to
oxaliplatin [4,5]. The mild hypersensitivity reaction
(grade 1 or 2) usually responds to discontinuation of
oxaliplatin and supportive treatment with antihistamine
agents and steroid. Frequently, patients with mild hyper-
sensitivity reaction can be re-treated with oxaliplatin by
adding appropriate pre-medications such as antihista-
mine agents and steroid, and increasing infusion time
with more diluted concentration [5,6]. Severe and
potentially fatal hypersensitivity reaction with sympto-
matic bronchospasm, angioedema, hypotension and ana-
phylaxis, occurred in about 2% of patients receiving
oxaliplatin treatment [7,8]. Although the manufacturer
recommends not to re-treat with oxaliplatin after the
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zation protocol has been successfully implemented in
patients with grade 3 hypersensitivity [9].
Here, we describe two cases of acute thrombocytope-
nia with concurrent oxaliplatin-induced hypersensitivity
reaction in patients with metastatic CRC. Both patients
had prior oxaliplatin treatment without occurrence of
hypersensitivity, or acute thrombocytopenia and received
oxaliplatin several years later due to disease progression
with non-responsiveness to other chemotherapeutic
regimens.
Case Presentation
Case one
A 60-year-old African-American male was diagnosed
with stage IV rectosigmoid colon cancer with liver
metastasis in 2004. He underwent abdominoperineal
resection of rectosigmoid cancer followed by six months
of FOLFOX chemotherapy with partial response in liver
metastasis. Subsequently, he received pelvic chemoradia-
tion with capecitabine. However, the liver metastasis
progressed while waiting for surgical evaluation. He
received FOLFOX and bevacizumab, 10 months after
the last dose of FOLFOX. After three cycles of treat-
ment, oxaliplatin was replaced by irinotecan because of
persistent grade 2 neuropathy. Due to disease progres-
sion, he was given additional treatment with bevacizu-
mab, irinotecan and panitumumab with disease
stabilization lasting for more than 12 months. Subse-
quently, radiofrequency ablation of the two hepatic
metastatic lesions was performed. He developed conges-
tive heart failure requiring warfarin treatment, and beva-
cizumab was discontinued.
In December 2008, due to disease progression and
improvement of neuropathy, he was restarted on dose-
reduced FOLFOX, with oxaliplatin 70 mg/m
2 plus leu-
covorin (LV) 400 mg/m
2 intravenous infusion over two
hours followed by 5-fluorouracil (5-FU) 2400 mg/m
2
infusion over 46 hours every two weeks. In mid-January
2009, during the third cycle of chemotherapy, one hour
into a planned two-hour infusion of oxaliplatin and LV,
he developed hypersensitivity reaction with rigors, chills,
bronchospasm and decreased oxygen saturation. Che-
motherapy infusion was immediately discontinued. The
symptoms resolved after the patient received oxygen
supplementation, antihistamine agents and steroid. Infu-
sion of oxaliplatin and LV was resumed and was com-
pleted with a slower infusion rate. However, he
experienced mild gingival bleeding at the end of infusion
and was instructed to return to clinic if the condition
worsened. In the evening, he developed epistaxis with
persistent gingival bleeding and had bright red blood
emanating from the colostomy site. He was found to
have prominent skin petechiae, bruises and tongue
hematoma the next day (Fig. 1A and 1B). Complete
blood count (CBC) showed an abrupt and marked
decrease in platelet count from 226 × 10
9/L (measured
one day prior to chemotherapy) to 4 × 10
9/L about 24
hours after the oxaliplatin infusion. Leukocyte and ery-
throcyte counts, hemoglobin and hematocrit levels were
within the normal reference range. Peripheral blood
smear revealed severe decrease in platelets, with mini-
mal schistocytosis. No blasts or atypical cells were
observed (Fig. 2A). The prothrombin time was mildly
prolonged with an International Normalized Ratio (INR)
of 1.9 due to warfarin prophylaxis for congestive heart
failure. Warfarin was discontinued to help control
Figure 1 Photographs form patient one taken 24 hours after
oxaliplatin infusion. A. Intense epistaxis with placement of nasal
packing, and tongue-hematoma formation. B. Upper extremity
petechiae, bruises and accumulation of blood in the colostomy.
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formed at the BloodCenter of Wisconsin (Milwaukee,
WI) and revealed presence of both non-specific Immu-
noglobulin G (IgG) and oxaliplatin-induced, IgG platelet
antibodies. Additional studies such as human immuno-
deficiency virus (HIV) testing, hepatitis B and C screen-
ing, and antinuclear antibody (ANA) analysis have been
performed to exclude other causes of thrombocytopenia.
Each yielded a negative result.
He was admitted for prompt management and
received two consecutive apheresis platelet transfusions,
and one adult unit of plasma. The platelet count
increased to 51 × 10
9/L with resolution of bleeding
overnight. He was sent home after two days of
observation without requiring additional platelet infu-
sions. Follow-up CBC measurements showed increasing
platelet counts, ultimately reaching a normal level within
twelve days after the incident (Fig. 3A). His warfarin
treatment was resumed after resolution of thrombocyto-
penia. His cancer-related symptoms remained stable,
with decreasing CEA levels for three months, even with-
out the use of chemotherapy. An abdominal CT scan
performed one month after the hypersensitivity reaction
indicated stable disease. However, three months after,
he experienced mild cancer-related symptom, requiring
resumption of chemotherapy with 5-FU and LV. Bevaci-
zumab was later added due to disease progression. He
did not experience any hypersensitivity reaction or acute
thrombocytopenia with these drugs.
Case two
A 66-year-old Hispanic female with type 2 diabetes mel-
litus, degenerative arthritis, and diverticulitis was diag-
nosed with stage IV colon cancer with lung and liver
metastases in 2006 after surgical resection of sigmoid
colon cancer. She was treated with first-line chemother-
apy including bevacizumab, capecitabine and oxaliplatin
from March 2007. Oxaliplatin was discontinued after
four months of treatment due to severe neuropathy. At
that time, she achieved disease stabilization with gradual
decline of CEA levels. She continued to receive bevaci-
zumab and capecitabine for eight months until disease
progression. Subsequently, she was enrolled in a clinical
study and received cetuximab, bevacizumab and irinote-
can for four months with good control of disease. She
was withdrawn from the clinical trial due to significant
toxicities. Afterwards, she developed progressive disease
on single-agent cetuximab.
In January 2009, with improvement of neuropathy sec-
ondary to prior oxaliplatin use, chemotherapy with bev-
acizumab, oxaliplatin and 5-FU every two weeks was
initiated. She tolerated the first two cycles without
major side effects. In early March 2009, during her third
cycle of chemotherapy, she experienced upper body skin
rash and pruritis shortly (5-10 minutes) after starting
oxaliplatin treatment. Oxaliplatin infusion was discon-
tinued immediately. The hypersensitivity symptoms
resolved after steroid and antihistamine treatment. No
petechiae or mucosal bleeding was noted. Due to our
prior experience with patient one, a CBC was immedi-
ately obtained after the onset of hypersensitivity symp-
toms. A drop in platelet count from 87 × 10
9/L to 66 ×
10
9/L was noted despite only receiving a small fraction
(less than 1/10) of planned oxaliplatin treatment. Her
platelet count was 99 × 10
9/L fifteen days prior to this
event (Fig 3B). A peripheral blood smear confirmed
moderate decrease in platelets with normal morphology
(Fig. 2B). No schistocytes were identified. Oxaliplatin
Figure 2 Peripheral blood smears.A .P a t i e n to n e :m a r k e d l y
decreased platelets without significant schistocytosis. (Wright’s stain,
1,000×) B. Patient two: moderate decline in platelets. (Wright’s stain,
1,000×)
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oxaliplatin infusion, with concurrent bleeding diathesis. Two units of apheresis platelets were provided. B: Patient two: moderate decrease in
platelet count without evidence of bleeding. Platelet drop was not as drastic as patient one due to discontinuation of the rest of oxaliplatin
treatment.
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reaction with concomitant mild thrombocytopenia; a
presentation similar to patient 1. A serum sample for
platelet antibody analysis was also sent to the BloodCen-
ter of Wisconsin (Milwaukee, WI), which later demon-
strated the presence of IgG oxaliplatin-induced platelet
antibody. The other CBC parameters revealed mild
decrease in WBC count, with normal hemoglobin and
hematocrit levels. Coagulation panel and bilirubin were
also within the normal reference range. HIV, hepatitis B
and C screening, and ANA analysis were all negative.
The possibility of a platelet transfusion was offered and
discussed in case of aggravation of the thrombocytope-
nia. However, the patient declined infusion of blood
products due to religious background. Oral prednisone
(20 mg, three times a day, for two days) was prescribed.
Her subsequent platelet counts gradually increased
within two weeks (Fig. 3B). She resumed chemotherapy
with bevacizumab, 5-FU and LV without significant
thrombocytopenia or hypersensitivity reaction. Nonethe-
less, she developed progressive disease several weeks
later. She was consequently treated with bevacizumab,
irinotecan and 5-FU without any evidence of hypersensi-
tivity reaction or acute thrombocytopenia.
Conclusion
We describe two cases of immune-mediated thrombocy-
topenia immediately following the onset of the hyper-
sensitivity reaction in patients with metastatic CRC
receiving oxaliplatin treatment. To our knowledge, this
is the first report demonstrating the association between
de novo oxaliplatin-induced hypersensitivity reaction and
immune-mediated thrombocytopenia from oxaliplatin.
Both patients received FOLFOX chemotherapy several
years prior without hypersensitivity symptoms or evi-
dence of acute thrombocytopenia. However, both
patients experienced hypersensitivity reaction on retreat-
ment with oxaliplatin. In both cases, acute thrombocyto-
penia transpired immediately after the occurrence of
hypersensitivity symptoms. Our first patient developed
severe thrombocytopenia with mucocutaneous bleeding
after completing the rest of oxaliplatin treatment, and
was hospitalized for platelet transfusion and close obser-
vation. For our second patient, a Jehovah’s Witness, oxa-
liplatin infusion was not resumed after the occurrence of
hypersensitivity reaction with moderate thrombocytope-
nia. Both patients had oxaliplatin appended to their
drug allergy list to prevent re-exposure.
In order to verify that the isolated, precipitous drop in
platelet counts was due to oxaliplatin, serum samples
from our two patients were collected and sent for drug-
induced platelet antibody analyses to the BloodCenter of
Wisconsin (Milwaukee, WI). Detection of oxaliplatin-
dependent antibodies in patients’ sera was performed via
flow cytometry [3]. Normal group O platelets were incu-
b a t e dw i t ht e s ts e r u mi nt h ep r e s e n c ea n da b s e n c eo f
oxaliplatin and were washed twice in buffer containing
oxaliplatin at the same concentration as in the primary
incubation mixture. Platelet-associated immunoglobulins
were then detected by flow cytometry using fluorescein
isothiocyanate-tagged anti-human IgG (Fcg-specific) and
phycoerythrin-tagged anti-human IgM (Fcm-specific).
Sera from normal, healthy donors, and sera containing
previously identified quinine-dependent platelet antibo-
dies served as negative and positive controls, respec-
tively. A positive reaction was defined as a mean platelet
fluorescence intensity at least twice that of platelets pro-
cessed identically except for the absence of oxaliplatin.
A ss h o w ni nF i g .4 ,p a t i e n t s ’ sera were incubated with
normal group O platelets in the absence and presence
of oxaliplatin. Both patients were confirmed to have
oxaliplatin-dependent IgG platelet antibodies. In patient
1, a weak non-drug-dependent antibody was also pre-
sent, and the significance of which is uncertain.
Drug-induced immune-mediated thrombocytopenia
(DIIT) is diagnosed by demonstrating an antibody in the
patient’s serum that reacts with normal platelets in the
presence of soluble drug [10]. Fewer than 10 che-
motherapeutic agents have been shown to cause DIIT
[3]. In patients receiving chemotherapy, thrombocytope-
nia is usually due to myelosuppression; however, acute
thrombocytopenia of unknown cause should prompt
suspicion for this entity. For DIIT, discontinuation of
the offending drug is the most important treatment. Pla-
telet transfusion is frequently needed when severe
thrombocytopenia occurs with consequent mucocuta-
neous bleeding as in Patient 1. Whether corticosteroids
are helpful is uncertain. Both our patients developed
DIIT despite receiving dexamethasone as part of antie-
metic regimen prior to oxaliplatin treatment.
Immune-mediated thrombocytopenia has been recog-
nized as a rare adverse outcome of oxaliplatin infusion
and has been identified in approximately 7% of allergic-
type reactions to oxaliplatin in a retrospective analysis
[ 1 1 ] .W eh a v es u m m a r i z e da l lp u b l i s h e dc a s er e p o r t s
related to oxaliplatin-induced acute thrombocytopenia in
table S1 (see additional file 1) [3,12-14] and table S2 (see
additional file 2) [15-25], with table S2 reflecting reports
without documentation of oxaliplatin-induced platelet
antibodies. Each patient received prior oxaliplatin treat-
ment, and all except one had metastatic CRC. Affected
patients were predominately female. As shown in table S2
(additional file 2), acute thrombocytopenia with hemolysis
(Evan’s syndrome) has also been described in patients with
hypersensitivity reaction from oxaliplatin. Furthermore,
most patients with Evan’s syndrome or hemolytic uremic
syndrome likely from multiple exposures to oxaliplatin,
presented with back pain during oxaliplatin infusion.
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pancytopenia four hours after the 15
th oxaliplatin treat-
ment in a patient with advanced CRC [12]. They identi-
fied oxaliplatin-dependent antibodies to platelets, red
blood cells and neutrophils. The patient developed sig-
nificant pancytopenia upon re-treatment with oxaliplatin
30 minutes after infusion, with inception of hypersensi-
tivity reaction. Curtis et al. reported two patients with
metastatic CRC who developed acute thrombocytopenia
one to two days after repeated (more than 10 times)
oxaliplatin treatment [3]. Oxaliplatin-dependent antibo-
dies specific for the platelet glycoprotein IIb/IIIa com-
plex were identified in both patients’ sera. As
summarized in table S1 (additional file 1), primarily
female patients were more likely to develop immune-
mediated thrombocytopenia after repeated oxaliplatin
Figure 4 Detection of oxaliplatin-dependent platelet antibodies. The assay was performed by flow cytometry in patient one (A) and patient
two (B). Both patients had IgG antibodies that reacted strongly with normal platelets in the presence of 0.1 mg/ml oxaliplatin, but not in the
absence of drug. No reaction was obtained with normal serum in the presence of drug.
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observed in all cases after discontinuation of oxaliplatin.
The majority of patients received platelet transfusion.
Moreover, as shown in tables S1 and S2 (additional
files 1 and 2), some patients had received other che-
motherapeutic agents such as irinotecan, cetuximab,
bevacizumab and 5-FU after recovery from oxaliplatin-
induced acute thrombocytopenia, and none of them had
recurrent acute thrombocytopenia. This observation
indicates that oxaliplatin-induced platelet antibodies do
not cross-react with other chemotherapeutic agents. In
our report, patient 1 resumed treatment three months
later with 5-FU and LV, with later addition of bevacizu-
mab. Patient 2 received bevacizumab and 5-FU, with
addition of irinotecan. Neither patient experienced
recurrent hypersensitivity reaction or recurrent episode
of acute thrombocytopenia. Bozec et al. reported a case
of a 53-year-old male with metastatic CRC, previously
treated with FOLFOX, who presented with irinotecan-
induced immune thrombocytopenia 18 hours after the
onset of hypersensitivity reaction during the first irinote-
can treatment [26]. The patient experienced another
episode of hypersensitivity reaction followed by acute
thrombocytopenia during the second irinotecan infusion.
IgG platelet antibody in the presence of irinotecan was
identified in the serum. Since the patient developed
immune thrombocytopenia during the first irinotecan
infusion, the authors speculated that this patient’sd r u g -
dependent platelet antibody could have been prompted
by the previously administered chemotherapeutic agent
which appeared to possess the ability to cross-react with
irinotecan. It is likely that oxaliplatin might have been
the culprit in their case; however, analysis for the pre-
sence of oxaliplatin-dependent platelet antibody was not
performed to support this hypothesis.
Our report highlights the importance of promptly
recognizing the association between oxaliplatin-induced
hypersensitivity reaction and immune-mediated throm-
bocytopenia. Female patients with advanced CRC and
prior oxaliplatin exposure are more likely to develop
this consequence, although it may also occur in male
patients. Therefore, it is imperative that patients should
be thoroughly examined for signs and symptoms of
bleeding, with concurrent CBC evaluation even after
recovery from the hypersensitivity symptoms. Heigh-
tened vigilance and prompt testing may be helpful in
recognizing development of antibody in patients with
religious objections to transfusion before the onset of
severe thrombocytopenia. Patients usually respond to
discontinuation of oxaliplatin, with concurrent platelet
transfusion if indicated. Additional tests such as periph-
eral blood smear examination and direct antiglobulin
test are also helpful in assessing Evan’ss y n d r o m eo r
hemolytic-uremic syndrome if worsening anemia or
h e m o l y s i si sn o t e d .P a t i e n t sw i t hd o c u m e n t e do x a l i p l a -
tin-induced acute thrombocytopenia should not be re-
challenged with oxaliplatin and should have oxaliplatin
listed as a drug allergy.
Consent
Written informed consent was obtained from each
patient for publication of this case report and accompa-
nying images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
Additional file 1: Table S1. Oxaliplatin-induced immune-mediated
thrombocytopenia. Summary of all published case reports related to
oxaliplatin-induced acute thrombocytopenia with documentation of
oxaliplatin-induced platelet antibodies.
Additional file 2: Table S2. Other oxaliplatin-related acute
thrombocytopenia reports. Summary of all published case reports
related to oxaliplatin-induced acute thrombocytopenia without
documentation of oxaliplatin-induced platelet antibodies.
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